Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early versus late hormonal therapy: debating the issues.

E David Crawford1

  • 1Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center, Denver, Colorado 80010, USA.

Urology
|April 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.

Clinical genitourinary cancer·2026
Same author

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.

JCO oncology practice·2024
Same author

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.

Cancer·2024
Same author

Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.

Cancer medicine·2024
Same author

Editorial Comment on "Should Military Veterans Be Classified as High Risk for Prostate Cancer Screening? A Systematic Review and Meta-analysis".

Urology·2024

Early hormonal therapy and chemotherapy show survival benefits for select prostate cancer patients. Further research is ongoing to identify optimal treatment strategies for localized and advanced disease.

Area of Science:

  • Oncology
  • Urology

Background:

  • Hormonal therapy for prostate cancer was historically for advanced stages.
  • Emerging evidence indicates survival benefits with earlier intervention.

Purpose of the Study:

  • To review evidence for early hormonal therapy in prostate cancer.
  • To explore the role of chemotherapy in prostate cancer treatment.

Main Methods:

  • Review of studies on hormonal therapy for TNM stage T3 tumors and nodal metastases (D1).
  • Analysis of clinical data on chemotherapy combined with hormonal therapy.
  • Mention of nomograms and artificial neural network programs for outcome prediction.

Main Results:

  • Survival advantage observed with hormonal therapy plus irradiation in T3 tumors.

Related Experiment Videos

  • Longer survival in patients with nodal metastases (D1) receiving early hormonal therapy post-surgery.
  • Chemotherapy plus hormonal therapy improved response and survival in locally advanced disease (T3 or D2), but not metastatic tumors.

    • Conclusions:

    • Early hormonal therapy may benefit selected prostate cancer patients, particularly those with T3 tumors or nodal metastases.
    • Chemotherapy combined with hormonal therapy shows promise for locally advanced disease.
    • Continued investigation into early hormonal therapy and adjuvant chemotherapy is warranted.